Thalassemia Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Complete Blood Cell Test, Hemoglobin Test, Iron Deficiency Test, DNA Tests, Others), By End User, By Region, and Competition

Global Thalassemia Diagnostic market is anticipated to grow considerably in the forecast period of 2028 due to rising healthcare expenditure, supportive government policy, advancements in diagnostic technologies, growing awareness about thalassemia, and increasing prevalence of thalassemia.

Thalassemia is a genetic blood disorder that affects the production of hemoglobin, which is essential for the transportation of oxygen in the body. There are two main types of thalassemia: alpha thalassemia and beta thalassemia.

The market for global thalassemia diagnostics is driven by the increasing prevalence of thalassemia worldwide, coupled with growing awareness among people about the disease. According to a published report by Cureus, around 1.5% of the world's population, or about 100 million people, carry the genes for B-thalassemia, with the highest prevalence in Southeast Asia, the Middle East, and the Mediterranean region. The market for thalassemia diagnostics includes tests for screening, diagnosis, and monitoring of thalassemia. These tests include complete blood count, hemoglobin electrophoresis, DNA analysis, and others. The global thalassemia diagnostics market is expected to grow due to the increasing adoption of advanced diagnostic technologies, such as PCR and genetic testing, which offer higher accuracy and sensitivity in detecting thalassemia.

Geographically, the Asia Pacific and MENA regions dominate the thalassemia diagnostic market, owing to the high prevalence of thalassemia in the region. However, the market is also growing in other regions, such as North America and Europe especially in Turkey, due to increasing awareness about thalassemia and the availability of advanced diagnostic technologies. Therefore, it is expected that the demand for the global thalassemia diagnostic market is going to rise in the forecast period.

Growing Awareness About Thalassemia is Propelling the Demand for the Global Thalassemia Diagnostic Market

Thalassemia is a genetic blood disorder that affects millions of people worldwide. It is caused by mutations in the genes that control the production of hemoglobin, a protein that is responsible for carrying oxygen in the blood. Individuals with thalassemia produce fewer healthy red blood cells and are therefore at a higher risk of developing anemia, fatigue, and other complications. The disorder is particularly prevalent in countries around the Mediterranean, Middle East, and Asia, where gene mutations are more usual. Globally, it is estimated that approximately 300-400 thousand children are born yearly with genetic substantial Hb diseases of which around 80 million children are transferors of B-thalassemia.

Growing awareness about thalassemia is propelling the demand for the global thalassemia diagnostic market. There is an increasing understanding of the disease among people, which has led to an increase in the number of people seeking diagnostic tests for thalassemia. The awareness has also increased the number of newborns and pregnant women being screened for thalassemia, which has further driven the demand for diagnostic tests.

The efforts of governments and healthcare organizations to educate people about the disease are one of the main drivers of the growing awareness about thalassemia. Governments around the world have launched awareness campaigns to educate people about the importance of early detection and treatment of thalassemia. These campaigns have included public service announcements, seminars, and workshops for healthcare professionals and the public. Such as Turkey Hemoglobinopathy Control Program has been initiated in 33 provinces of Turkey to screen and create awareness about B-thalassemia and its symptoms.

In addition to government initiatives, healthcare organizations, and patient advocacy groups have also played a significant role in raising awareness about thalassemia. These organizations have provided information about the disease to patients and their families, as well as to healthcare professionals. They have also offered support and resources to individuals with thalassemia and their families. The FDA or the European Medicines Agency (EMA) has granted orphan drug designation (ODD) to Beta Thalassemia drugs. Through this ODD, companies can get incentives to invest in rare disease treatments.

Another factor contributing to the growing awareness about thalassemia is the availability of information on the internet. Patients and their families can access information about the disease, including its symptoms, causes, and treatment options. The internet has also provided a platform for patient communities to connect and share their experiences, which has helped to increase awareness about the disease.

The growing awareness about thalassemia has led to an increase in the demand for thalassemia diagnostic tests. Diagnostic tests for thalassemia include blood tests, DNA analysis, and hemoglobin electrophoresis. These tests are used to screen, diagnose, and monitor the disease. With increased awareness about the disease, more people are seeking diagnostic tests, which has driven the demand for thalassemia diagnostic tests. Therefore, all these factors are expected to drive the demand for the global thalassemia diagnostic market in the forecast period.

Favorable Government Policies are Key drivers that Drive the Thalassemia Diagnostic Market Growth

Supportive government policies have been a driving force in influencing the demand for the global thalassemia diagnostic market. Governments around the world have recognized the need to address the increasing burden of thalassemia on their healthcare systems and have taken steps to support the development and use of thalassemia diagnostic tests. Individuals with thalassemia produce fewer healthy red blood cells and are at a higher risk of developing anemia, fatigue, and other complications. The disorder is particularly prevalent in countries around the Mediterranean, Middle East, and Asia, where the gene mutations are more common.

The primary method by which supportive government policies have influenced the demand for thalassemia diagnostic tests is through funding and investment. Governments have invested in research and development of new and improved diagnostic tests for thalassemia, which has led to the development of more accurate and efficient tests. Governments have also provided funding to increase access to diagnostic tests, particularly in developing countries where the prevalence of thalassemia is high. For instance, the "Premarital Screening" in which a couple planning to get married soon needs to undergo several tests to check genetic blood disorders (e.g. sickle cell anemia and thalassemia and sickle cell anemia) and infectious diseases (e.g. hepatitis B, hepatitis C, and HIV/AIDS) in Saudi Arabia.

Governments have also implemented policies that require mandatory screening for thalassemia. For example, in many countries, newborns are screened for thalassemia to identify those with the disorder early on and provide appropriate treatment. This has increased the demand for thalassemia diagnostic tests and has led to a greater need for accurate and reliable tests. Children with severe forms of thalassemia (such as thalassemia major) typically decease under 5 years of age and the average life expectancy of patients suffering from thalassemia is about 30 years, predominantly in seriously resource-constrained countries.

Furthermore, supportive government policies have helped to increase awareness about thalassemia and the importance of early diagnosis and treatment. Governments have launched awareness campaigns to educate the public about thalassemia and its impact on individuals and society. This has led to an increase in the number of people seeking diagnostic tests for thalassemia and has helped to reduce the stigma associated with the disorder.

Advancements in Diagnostic Technologies are Driving the Demand for Thalassemia Diagnostic Market Growth

Advancements in diagnostic technologies have played a significant role in driving the demand for thalassemia diagnostic tests in the market. These advancements have led to the development of more accurate and efficient tests, which have improved the quality of care for individuals with thalassemia. Genetic testing has revolutionized the diagnosis and management of many genetic disorders, including thalassemia. It involves analyzing an individual's DNA to identify specific genetic mutations associated with the disorder. This type of testing is highly accurate and can detect thalassemia even in individuals who do not exhibit symptoms. Point-of-care testing (POCT) allows for the rapid diagnosis of disease at the bedside or in the doctor's office. POCT devices are portable and can provide results in a matter of minutes, reducing the need for laboratory testing and improving patient care.

Market Segmentation

Global Thalassemia Diagnostic market is segmented based on type, end-user, and region. Based on type, the market is segmented into complete blood cell (CBC) tests, hemoglobin tests, iron deficiency tests, DNA tests, and others. Based on end-user, the market is fragmented into hospitals & clinics, diagnostic laboratories, and others. Based on region, the market is divided into North America, Europe, Asia Pacific, South America, Middle East & Africa.

Company Profiles

Hybribio Limited, Oasis Diagnostics Corporation, ViennaLab Diagnostics GmbH, GENETEK BIOPHARMA GmbH, Devyser Diagnostics AB, Yaneng BIOscience, Shenzhen) Co., Ltd., BioLab Diagnostics India Private Limited, NPT Co. Ltd., and Bio-Rad Laboratories, Inc. are some of the key players in the global thalassemia diagnostic market.

Report Scope:

In this report, global thalassemia diagnostic market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Thalassemia Diagnostic Market, By Type:

• Complete Blood Cell (CBC) Test
• Hemoglobin Test
• Iron Deficiency Test
• DNA Tests
• Others

Thalassemia Diagnostic Market, By End User:

• Hospitals & Clinics
• Diagnostic Laboratories
• Others

Thalassemia Diagnostic Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• Asia-Pacific
• China
• India
• Malaysia
• Thailand
• Vietnam
• South America
• Brazil
• Argentina
• Middle East & Africa
• Egypt
• South Africa
• Saudi Arabia
• UAE
• Turkey
• Kuwait
• Qatar
• Bahrain

Competitive landscape

• Company Profiles: Detailed analysis of the major companies present in the global Thalassemia Diagnostic market.

Available Customizations:

• With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).